Women’s health companies raised a record $1.55 billion in disclosed equity in 2025, up 39% year on year, according to The Road to the Era of Scale, the first Global Women’s Health Investment Report from W Group.
The report, built on proprietary tracking of more than 500 funding stories and 164 equity rounds, reveals a sector at its largest ever scale, with capital reaching more companies, categories and countries than at any point on record.
85 companies raised equity in 2025, the highest single-year count ever recorded, and ten rounds reached $50 million or more, double the number in 2024.
But the report’s central finding is not the headline number. It is that the money has stopped concentrating at the top. In 2024, the three largest rounds accounted for 39% of all disclosed capital; in 2025 that share fell to 32%, as funding to companies outside the top three grew 56% year on year.
That capital is creating markets almost overnight. GLP-1 and metabolic health, effectively a non-existent funding category a year ago, arrived with a $50 million Series A for SheMed. Endometriosis drew more than $57 million across five rounds spanning therapeutics, diagnostics and imaging. Oncology attracted the largest cheques, led by Tubulis (€308M), NUCLIDIUM (€84M) and Mercy ($59M).
The report also identifies a single structural risk: a Series A bottleneck. While 35 to 40 companies raise pre-seed and seed rounds each year, only around 20 to 25 reach Series A, and many companies that raised seed rounds in 2024 did not raise again in 2025.
“2025 was the biggest year women’s health has ever had, and the most important finding isn’t the headline number. It’s that the money has stopped pooling at the top. Capital is reaching more companies, more categories and more countries than ever before,” said Molly Taylor, head of content at W Group. “The Era of Scale is real. It’s just not finished, and the Series A gap is where it could stall. Closing that gap is the highest-leverage move this ecosystem can make in 2026.”
